O	0	2	De
O	2	3	-
O	3	13	escalation
O	14	24	strategies
O	25	27	in
O	28	32	HER2
O	32	33	-
O	33	41	positive
O	42	47	early
O	48	54	breast
O	55	61	cancer
O	62	63	(
O	63	66	EBC
O	66	67	)
O	67	68	:
O	69	74	final
O	75	83	analysis
O	84	86	of
O	87	90	the
O	91	94	WSG
O	94	95	-
O	95	100	ADAPT
O	101	105	HER2
O	105	106	+
O	106	107	/
O	107	109	HR
O	109	110	-
O	111	116	phase
O	117	119	II
O	120	125	trial
O	125	126	:
O	127	135	efficacy
O	135	136	,
O	137	143	safety
O	143	144	,
O	145	148	and
O	149	159	predictive
O	160	167	markers
O	168	171	for
O	172	174	12
O	175	180	weeks
O	181	183	of
O	184	195	neoadjuvant
O	196	200	dual
O	201	209	blockade
O	210	214	with
B-intervention	215	226	trastuzumab
I-intervention	227	230	and
I-intervention	231	241	pertuzumab
I-intervention	242	243	±
I-intervention	244	250	weekly
I-intervention	251	261	paclitaxel
O	261	262	.

O	263	271	Response
O	272	277	rates
O	278	280	in
O	281	285	HER2
O	285	286	-
O	286	300	overexpressing
O	301	304	EBC
O	305	312	treated
O	313	317	with
O	318	329	neoadjuvant
O	330	342	chemotherapy
O	343	346	and
O	347	358	trastuzumab
O	359	360	(
O	360	361	T
O	361	362	)
O	363	367	have
O	368	372	been
O	373	381	improved
O	382	384	by
O	385	393	addition
O	394	396	of
O	397	407	pertuzumab
O	408	409	(
O	409	410	P
O	410	411	)
O	411	412	.

O	413	416	The
O	417	428	prospective
O	428	429	,
O	430	435	phase
O	436	438	II
O	438	439	,
O	440	451	neoadjuvant
O	452	455	WSG
O	455	456	-
O	456	461	ADAPT
O	462	466	HER2
O	466	467	+
O	467	468	/
O	468	470	HR
O	470	471	-
O	472	477	trial
O	478	486	assessed
O	487	494	whether
O	495	503	patients
O	504	508	with
O	509	515	strong
O	516	521	early
O	522	530	response
O	531	533	to
O	534	538	dual
O	539	547	blockade
O	548	553	alone
O	554	559	might
O	560	567	achieve
O	568	580	pathological
O	581	589	complete
O	590	598	response
O	599	600	(
O	600	603	pCR
O	603	604	)
O	605	615	comparable
O	616	618	to
O	619	623	that
O	624	626	of
O	627	635	patients
O	636	645	receiving
O	646	650	dual
O	651	659	blockade
O	660	663	and
O	664	676	chemotherapy
O	676	677	.

B-eligibility	678	684	Female
I-eligibility	685	693	patients
I-eligibility	694	698	with
I-eligibility	699	703	HER2
I-eligibility	703	704	+
I-eligibility	704	705	/
I-eligibility	705	707	HR
I-eligibility	707	708	-
I-eligibility	709	712	EBC
I-eligibility	713	714	(
I-eligibility	714	716	M0
I-eligibility	716	717	)
O	718	722	were
O	723	733	randomized
O	734	735	(
O	735	736	5
O	736	737	:
O	737	738	2
O	738	739	)
O	740	742	to
O	743	745	12
O	746	751	weeks
O	752	754	of
O	755	756	T
O	757	758	+
O	759	760	P
O	761	762	±
O	763	769	weekly
O	770	780	paclitaxel
O	781	782	(
O	782	785	pac
O	785	786	)
O	787	789	at
O	790	792	80
O	793	795	mg
O	795	796	/
O	796	798	m2
O	798	799	.

O	800	805	Early
O	806	814	response
O	815	818	was
O	819	826	defined
O	827	829	as
O	830	843	proliferation
O	844	852	decrease
O	853	854	≥
O	854	856	30
O	856	857	%
O	858	860	of
O	861	863	Ki
O	863	864	-
O	864	866	67
O	867	868	(
O	868	874	versus
O	875	883	baseline
O	883	884	)
O	885	887	or
O	888	891	low
O	892	903	cellularity
O	904	905	(
O	905	906	<
O	906	909	500
O	910	918	invasive
O	919	924	tumor
O	925	930	cells
O	930	931	)
O	932	934	in
O	935	938	the
O	939	940	3
O	940	941	-
O	941	945	week
O	946	952	biopsy
O	952	953	.

O	954	957	The
O	958	963	trial
O	964	967	was
O	968	976	designed
O	977	979	to
O	980	984	test
O	985	988	non
O	988	989	-
O	989	1000	inferiority
O	1001	1004	for
O	1005	1008	pCR
O	1009	1011	in
O	1012	1017	early
O	1018	1028	responding
O	1029	1037	patients
O	1038	1040	of
O	1041	1044	the
O	1045	1046	T
O	1047	1048	+
O	1049	1050	P
O	1051	1054	arm
O	1055	1061	versus
O	1062	1065	all
O	1066	1078	chemotherapy
O	1078	1079	-
O	1079	1086	treated
O	1087	1095	patients
O	1095	1096	.

O	1097	1101	From
O	1102	1110	February
O	1111	1115	2014
O	1116	1118	to
O	1119	1127	December
O	1128	1132	2015
O	1132	1133	,
B-total-participants	1134	1137	160
O	1138	1146	patients
O	1147	1151	were
O	1152	1160	screened
O	1160	1161	,
B-control-participants	1162	1164	92
O	1165	1169	were
O	1170	1180	randomized
O	1181	1183	to
B-control	1184	1185	T
I-control	1186	1187	+
I-control	1188	1189	P
O	1190	1193	and
B-intervention-participants	1194	1196	42
O	1197	1199	to
O	1200	1201	T
O	1202	1203	+
O	1204	1205	P
O	1205	1206	+
O	1206	1209	pac
O	1209	1210	.

O	1211	1219	Baseline
O	1220	1235	characteristics
O	1236	1240	were
O	1241	1245	well
O	1246	1254	balanced
O	1255	1256	(
O	1256	1262	median
O	1263	1266	age
O	1267	1269	54
O	1270	1276	versus
O	1277	1279	51
O	1279	1280	.
O	1280	1281	5
O	1282	1287	years
O	1287	1288	,
O	1289	1292	cT2
O	1293	1295	51
O	1295	1296	.
O	1296	1297	1
O	1298	1304	versus
O	1305	1307	52
O	1307	1308	.
O	1308	1309	4
O	1309	1310	%
O	1310	1311	,
O	1312	1315	cN0
O	1316	1318	54
O	1318	1319	.
O	1319	1320	3
O	1321	1327	versus
O	1328	1330	61
O	1330	1331	.
O	1331	1332	9
O	1332	1333	%
O	1333	1334	)
O	1334	1335	;
O	1336	1338	91
O	1338	1339	.
O	1339	1340	3
O	1340	1341	%
O	1342	1344	of
O	1345	1353	patients
O	1354	1363	completed
O	1364	1365	T
O	1366	1367	+
O	1368	1369	P
O	1370	1373	per
O	1374	1382	protocol
O	1383	1386	and
O	1387	1389	92
O	1389	1390	.
O	1390	1391	9
O	1391	1392	%
O	1393	1394	T
O	1395	1396	+
O	1397	1398	P
O	1398	1399	+
O	1399	1402	pac
O	1402	1403	.

O	1404	1407	The
B-outcome	1408	1411	pCR
I-outcome	1412	1416	rate
O	1417	1419	in
O	1420	1423	the
O	1424	1425	T
O	1426	1427	+
O	1428	1429	P
O	1429	1430	+
O	1430	1433	pac
O	1434	1437	arm
O	1438	1441	was
B-iv-bin-percent	1442	1444	90
I-iv-bin-percent	1444	1445	.
I-iv-bin-percent	1445	1446	5
I-iv-bin-percent	1446	1447	%
O	1447	1448	,
O	1449	1457	compared
O	1458	1462	with
B-cv-bin-percent	1463	1465	36
I-cv-bin-percent	1465	1466	.
I-cv-bin-percent	1466	1467	3
I-cv-bin-percent	1467	1468	%
O	1469	1471	in
O	1472	1475	the
O	1476	1477	T
O	1478	1479	+
O	1480	1481	P
O	1482	1485	arm
O	1486	1488	as
O	1489	1490	a
O	1491	1496	whole
O	1496	1497	.

O	1498	1500	In
O	1501	1504	the
O	1505	1506	T
O	1507	1508	+
O	1509	1510	P
O	1511	1514	arm
O	1514	1515	,
B-cv-bin-abs	1516	1518	24
O	1518	1519	/
B-control-participants	1519	1521	92
O	1522	1526	were
O	1527	1537	classified
O	1538	1540	as
B-outcome	1541	1544	non
I-outcome	1544	1545	-
I-outcome	1545	1555	responders
O	1555	1556	,
O	1557	1560	and
O	1561	1566	their
B-outcome	1567	1570	pCR
I-outcome	1571	1575	rate
O	1576	1579	was
O	1580	1584	only
B-cv-bin-percent	1585	1586	8
I-cv-bin-percent	1586	1587	.
I-cv-bin-percent	1587	1588	3
I-cv-bin-percent	1588	1589	%
O	1590	1598	compared
O	1599	1603	with
B-iv-bin-percent	1604	1606	44
I-iv-bin-percent	1606	1607	.
I-iv-bin-percent	1607	1608	7
I-iv-bin-percent	1608	1609	%
O	1610	1612	in
B-outcome	1613	1623	responders
O	1624	1625	(
B-iv-bin-abs	1625	1627	38
O	1627	1628	/
B-intervention-participants	1628	1630	92
O	1630	1631	)
O	1632	1635	and
B-iv-bin-percent	1636	1638	42
I-iv-bin-percent	1638	1639	.
I-iv-bin-percent	1639	1640	9
I-iv-bin-percent	1640	1641	%
O	1642	1644	in
O	1645	1653	patients
O	1654	1658	with
B-outcome	1659	1671	unclassified
I-outcome	1672	1677	early
I-outcome	1678	1686	response
O	1687	1688	(
B-iv-bin-abs	1688	1690	30
O	1690	1691	/
B-intervention-participants	1691	1693	92
O	1693	1694	)
O	1694	1695	.

O	1696	1698	No
O	1699	1702	new
O	1703	1709	safety
O	1710	1717	signals
O	1718	1722	were
O	1723	1731	observed
O	1732	1734	in
O	1735	1738	the
O	1739	1744	study
O	1745	1755	population
O	1755	1756	.

O	1757	1765	Addition
O	1766	1768	of
O	1769	1775	taxane
O	1776	1787	monotherapy
O	1788	1790	to
O	1791	1795	dual
O	1796	1800	HER2
O	1801	1809	blockade
O	1810	1812	in
O	1813	1814	a
O	1815	1817	12
O	1817	1818	-
O	1818	1822	week
O	1823	1834	neoadjuvant
O	1835	1842	setting
O	1843	1856	substantially
O	1857	1866	increases
O	1867	1870	pCR
O	1871	1876	rates
O	1877	1879	in
O	1880	1884	HER2
O	1884	1885	+
O	1885	1886	/
O	1886	1888	HR
O	1888	1889	-
O	1890	1893	EBC
O	1894	1902	compared
O	1903	1907	with
O	1908	1912	dual
O	1913	1921	blockade
O	1922	1927	alone
O	1927	1928	,
O	1929	1933	even
O	1934	1940	within
O	1941	1946	early
O	1947	1957	responders
O	1958	1960	to
O	1961	1965	dual
O	1966	1974	blockade
O	1974	1975	.

O	1976	1981	Early
O	1982	1985	non
O	1985	1986	-
O	1986	1994	response
O	1995	2000	under
O	2001	2005	dual
O	2006	2014	blockade
O	2015	2023	strongly
O	2024	2032	predicts
O	2033	2040	failure
O	2041	2043	to
O	2044	2051	achieve
O	2052	2055	pCR
O	2055	2056	.
